Paul Bröckelmann: You don’t see a study on Hodgkin Lymphoma published in Science Magazine everyday
Paul Bröckelmann, Physician Scientist at MPI for Biology of Ageing, shared on X:
“You don’t see a study on Hodgkin Lymphoma published in Science Magazine everyday and this paper from the Teijaro Lab indeed is exciting: JAK inhibition enhances ICI in patients with HL by reprogramming of myeloid cells to a immunostimulatory state.”
Andrew M. Evens, Deputy Director at Rutgers Cancer Institute, replied:
“Super kudos to Masonic Cancer Center’s Dr. Bachanova for leading this HL clinical trial for the Big Ten Cancer Research Consortium (together with The University of Iowa Holden Comprehensive Cancer Center’s Dr Farooq and UW Health’s Dr Kenkere).
Amazing translational science. The Big 10 CRC lymphoma team is just getting started!”
Source: Paul Bröckelmann/X and Andrew M. Evens/X
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Authors: Jaroslav Zak, Isaraphorn Pratumchai, Brett S. Marro, Kristi L. Marquardt, Reza Beheshti Zavareh, Luke L. Lairson, Michael B. A. Oldstone, Judith A. Varner, Livia Hegerova, Qing Cao, Umar Farooq, Vaishalee P. Kenkre, Veronika Bachanova, and John R. Teijaro
